Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Let large language models judge each other: multi-agent peer-reviewed reasoning for medical question answering.

Journal of the American Medical Informatics Association : JAMIA·2026
Same author

Association of chronic disease risk and physical activity measured by wearable devices in the All of Us program.

Communications medicine·2026
Same author

Identifying Over- and Underfunded Diseases by Comparing National Institutes of Health Funding for Skin Disease Research With US Skin Disease Burden According to 2021 Global Burden of Disease Data: Cross-Sectional Analysis.

JMIR dermatology·2026
Same author

Utilizing the VISIA Camera for Analyzing 5-Fluorouracil Treatment Efficacy for Actinic Keratosis.

JMIR dermatology·2025
Same author

Benchmarking retrieval-augmented large language models in biomedical NLP: Application, robustness, and self-awareness.

Science advances·2025
Same author

Advantages of a Virtual Collaborative Research Dermatology Laboratory.

JMIR medical education·2025

Related Experiment Video

Updated: Jun 20, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.3K

Antidiabetic Drug Associations With Heart Failure Outcomes: Real-World Evidence Study Using Electronic Health

Elzbieta Jodlowska-Siewert1, Yunhui Chen2, Sinian Zhang1

  • 1Division of Biostatistics and Health Data Science, School of Public Health, University of Minnesota, 2221 University Ave SE, Suite 200, Minneapolis, MN, 55414, United States, 1 612-624-4655.

JMIR Diabetes
|April 15, 2026
PubMed
Summary
This summary is machine-generated.

Patients with type 2 diabetes mellitus treated with sulfonylureas showed better 5-year heart failure survival compared to insulin. This real-world study highlights differing cardiovascular outcomes among type 2 diabetes mellitus therapies.

Keywords:
comparative effectivenessdipeptidyl peptidase-4 inhibitorsglucagon-like peptide-1 receptor agonistsinsulinnatural language processingsulfonylureas

More Related Videos

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

793

Related Experiment Videos

Last Updated: Jun 20, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.3K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

793

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (T2D) significantly increases cardiovascular disease risk, particularly heart failure (HF).
  • Real-world data comparing T2D therapies for HF outcomes are limited.
  • Understanding comparative effectiveness is crucial for managing T2D and cardiovascular risk.

Purpose of the Study:

  • To compare the time-to-heart failure (HF) in patients with T2D initiating specific second-line therapies after metformin.
  • To evaluate HF risk and survival rates associated with different drug classes.

Main Methods:

  • Retrospective analysis of electronic health records for 939 T2D patients.
  • Comparison groups: sulfonylureas vs. insulin, and GLP1 receptor agonists (GLP1 RAs) vs. DPP-4 inhibitors (DPP4i).
  • Doubly robust causal estimation used to adjust for confounding factors.

Main Results:

  • Sulfonylureas were associated with significantly higher 5-year HF-free survival compared to insulin (P=.01).
  • No significant difference in 5-year HF-free survival was observed between GLP1 RAs and DPP4i (P=.40).
  • No significant differences in HF-related hospitalization rates were found between the compared drug pairs.

Conclusions:

  • Real-world evidence suggests sulfonylureas may offer better HF-free survival than insulin in T2D patients.
  • No significant HF outcome differences were found between GLP1 RAs and DPP4i.
  • Limitations include potential confounding and sample size; further research is warranted.